Wegovy, also containing semaglutide, is a higher-dose version of Ozempic specifically developed for weight loss
72-hour notice required before billing date LegitScript reference: FeelGood's official site displays a LegitScript verification reference
Sermorelin May Naturally Increase Testosterone The peptide can boost hormone production, and works even better with TRT Testosterone replacement therapy (TRT) is the go-to, evidence-based method for boosting mens testosterone levels
Theoretical analysis of electronic absorption spectra of vitamin B12 models
pipeline lists Phase 2 4D-1754D-175 / Complement factor H / complement pathway / Intravitreal AAV genetic medicine / RetinaGeographic atrophySeeking partnerships to advance 4D-7254D-725 / Aerosol-delivered AAV genetic medicine / PulmonologyAlpha-1 antitrypsin lung diseasePreclinicalSeeking partnerships to advance 4assets 4assets MRT-6160MRT-6160 / VAV1 / Oral molecular glue degrader / Immunology & InflammationImmune-mediated diseasesClinical MRT-8102MRT-8102 / NEK7 / Oral molecular glue degrader / Immunology & InflammationIL-1/NLRP3-driven inflammatory diseasesPhase 1 MRT-2359MRT-2359 / GSPT1 / Oral molecular glue degrader / OncologyCastration-resistant prostate cancerPhase 1/2Ongoing Cyclin E1 degrader programCCNE1 / CDK2 / Molecular glue degrader / OncologyCCNE1-amplified tumorsPreclinicalLead optimizationER+ breast cancerPreclinicalLead optimization 4assets HCW9302HCW9302 / IL-2R / IL-2 fusion protein / AutoimmuneAlopecia areataPhase 1OngoingUS HCW11-006HCW11-006 / Multiple cytokines (IL-15/IL-15R, IL-7, IL-21, IL-2) / Multi-functional fusion immunotherapeutic / OncologyCancerPhase 1Planned by licenseeChina HCW11-018bHCW11-018b / Tissue Factor/CD3 / Tetra-valent bispecific T-cell engager (Big BiTE) / OncologySolid tumorsPreclinicalIND-enablingGlobal HCW11-040HCW11-040 / PD-1 (pembrolizumab-based) + TGF- / Tetra-valent immune checkpoint inhibitor fusion / OncologySolid tumorsPreclinicalIND-enablingGlobal 4assets nogapendekin alfa inbakiceptN-803 / ANKTIVA / IL-15 receptor / Cytokine fusion protein / Interleukin-15 superagonist / Oncology, Infectious DiseasesBCG Unresponsive NMIBC Carcinoma In-Situ & Papillary (QUILT-3.032)ApprovedMarketedUSBCG Nave NMIBC (QUILT-2.005)Phase 2/Phase 3ActiveUSNon-Small Cell Lung Cancer (ResQ201A)Phase 3ActiveGlobal PD-L1 t-haNKPD-L1 / Cell Therapy / Engineered NK cells / OncologyAdvanced Solid TumorsPhase 2ActiveUS AldoxAlbumin-bound doxorubicin complex / OncologyAdvanced Solid TumorsPhase 2ActiveUS Recombinant BCGVaccine / Immunotherapy / OncologyBladder CancerExpanded AccessActiveUS 4assets anzu-cel (IMA203)IMA203 / anzutresgene autoleucel / PRAME / Autologous TCR-T cell therapy / Solid Tumors2L+ cutaneous melanomaPhase 3ongoingUSEU5Uveal melanomaPhase 1bongoingUSEU5PRAME+ solid tumorsPhase 1ongoingUSEU5 IMA203CD8 (GEN2)IMA203CD8 / PRAME / Autologous TCR-T cell therapy (next-gen with CD8) / Solid TumorsPRAME+ advanced solid tumorsPhase 1dose escalation ongoingUSEU5Ovarian and endometrial cancersPhase 1ongoingUSEU5 IMA402IMA402 / PRAME / Half-life extended TCR bispecific (TCER) / Solid TumorsRecurrent/refractory solid tumors (melanoma, gynecologic, sqNSCLC)Phase 1/2Phase 1b expansion ongoingUSEU IMA401IMA401 / MAGEA4/8 / TCR bispecific (TCER) / Solid TumorsRecurrent/refractory solid tumors (HNSCC, sqNSCLC, melanoma)Phase 1dose escalation completedUSEU 4assets INB-100INB-100 / DeltEx Allo allogeneic T cell therapy / OncologyAcute leukemia post-HSCTPhase 1Expansion cohort enrollingUS INB-200INB-200 / DeltEx DRI autologous genetically modified T cell therapy / OncologyNewly diagnosed glioblastomaPhase 1Treatment completed
